How would a pharmaceutical company benefit from the Metaprise, Agent-based, strand commonality models 2025 to 2075

CASE STUDY SUBJECT: NOVARTIS

To evaluate how Jon W. Hansen’s models—Metaprise, Agent-Based Procurement, and the Theory of Strand Commonality—can benefit Novartis between 2025 and 2075, we must consider the unique characteristics of the pharmaceutical industry:

• Highly regulated environment (FDA, EMA, etc.)
• Extensive indirect spend (R&D, clinical trials, digital health platforms)
• Complex global supply chain (GxP-compliant sourcing, temperature-controlled logistics)
• Long development cycles (drug discovery to commercialization)
• Need for ethics, sustainability, and transparency in procurement

---

STRATEGIC IMPACT DOMAINS

---

HANSEN MODEL INFLUENCE ON NOVARTIS (2025–2075)

2025–2030: Compliance-Centric Metaprise Foundation

---

2030–2035: Clinical Procurement & Strand Transparency

---

2035–2040: Agent-Led Operational Ecosystem

---

2040–2045: Metaprise-Centric, Portfolio-Aware Procurement

---

2045–2050: Cognitive Procurement Orchestration

---

2050–2055: Self-Regulating Procurement Ecosystem

---

2055–2075: Autonomous & Ethical Metaprise

---

Why Hansen’s Models Are Especially Fit for Novartis

30

PROCURETECH SOLUTION PROVIDER ALIGNMENT

30